Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
Epistemonikos ID: 8d95ec7f067e412330fed2f0a85473cbf1996579
First added on: May 05, 2024